Rational Vaccines has developed the world’s first line of live-attenuated herpes simplex virus vaccines.

Retraining the immune system with rationally-engineered live vaccines.

Rational Vaccines (RVx) was formed in 2015 for the purpose of offering better solutions to stop the spread of herpes and alleviate the problems faced by people suffering with unrelenting, chronic disease.

For decades, acyclovir-related antiviral drugs have been the standard of medical care for treating herpes and have failed to curb the symptoms of herpetic disease in many patients.  Moreover, antiviral drugs have not curbed the epidemic spread of herpes simplex virus 1 and 2 (HSV-1 and HSV-2). Despite the availability of antiviral drugs, more than one million people continue to be newly infected with HSV-1 or HSV-2 every week.

RVx is developing the world’s first line of live HSV-1 and HSV-2 vaccines that bear attenuating mutations in the viral ICP0 protein, a critical positive regulator of HSV replication and reactivation.  These live HSV ICP0 mutant vaccines, TheravaxHSV and ProfavaxHSV, appear to be up to 100 times more effective than conventional HSV subunit vaccines. Coupled with our novel flow-cytometry based diagnostic technology, the HSV ABVIC Test, RVx is offering several new opportunities to improve the management and/or prevention of herpetic disease.


Social Impact Capital Philanthropic Direct


Velorum Capital Founders Fund Thiel Capital